Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis (Q81445112)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18549443%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18549443%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18549443%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

S Fabre

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18549443%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

N Dossat

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18549443%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

C Guisset

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18549443%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

J D Cohen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18549443%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

J P Cristol

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18549443%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

J P Daures

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18549443%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

C Jorgensen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18549443%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

18 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18549443%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Experimental Immunology

8 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18549443%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

153

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18549443%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18549443%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

188-195

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18549443%20AND%20SRC:MED&resulttype=core&format=json

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

8 January 2020

cites work

1 reference

12 December 2020

Evaluation of an immunoassay (Abbott-IMX Analyzer) allowing routine determination of sirolimus: comparison with LC-MS method

1 reference

12 December 2020

The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients

1 reference

12 December 2020

Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis

1 reference

12 December 2020

Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis

1 reference

12 December 2020

Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis

1 reference

12 December 2020

Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab

1 reference

12 December 2020

Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis

1 reference

12 December 2020

Fine-tuning of the prediction of mortality in hemodialysis patients by use of cytokine proteomic determination

1 reference

12 December 2020

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

12 December 2020

Factors predicting responsiveness to anti-TNFalpha therapy in patients with rheumatoid arthritis: using biotherapies rationally

1 reference

12 December 2020

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

1 reference

12 December 2020

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

12 December 2020

Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNFalpha therapy

1 reference

12 December 2020

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

12 December 2020

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

12 December 2020

Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis

1 reference

12 December 2020

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

12 December 2020

Involvement of ErbB-2 in rheumatoid synovial cell growth

1 reference

12 December 2020

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

1 reference

12 December 2020

A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis

1 reference

12 December 2020

Identification of NF-kappa B-regulated genes induced by TNFalpha utilizing expression profiling and RNA interference

1 reference

12 December 2020

Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis

1 reference

12 December 2020

Immunoturbidimetric determination of C-reactive protein (CRP) and high-sensitivity CRP on heparin plasma. Comparison with serum determination

1 reference

12 December 2020

Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?

1 reference

12 December 2020

Biphasic production of IL-8 in lipopolysaccharide (LPS)-stimulated human whole blood. Separation of LPS- and cytokine-stimulated components using anti-tumor necrosis factor and anti-IL-1 antibodies

1 reference

12 December 2020

Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis

1 reference

12 December 2020

Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium

1 reference

12 December 2020

Regulation of monocyte chemoattractant protein-1 gene expression and secretion in rat pulmonary alveolar macrophages by lipopolysaccharide, tumor necrosis factor-alpha, and interleukin-1 beta

1 reference

12 December 2020

Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis

1 reference

12 December 2020

Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis

1 reference

12 December 2020

Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept

1 reference

12 December 2020

Tumor necrosis factor alpha and epidermal growth factor act additively to inhibit matrix gene expression by chondrocyte

1 reference

12 December 2020

C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept

1 reference

12 December 2020

Gene-expression profiling: time for clinical application?

1 reference

12 December 2020

Overlapping gene expression profiles in rheumatoid fibroblast-like synoviocytes induced by the proinflammatory cytokines interleukin-1 beta and tumor necrosis factor

1 reference

12 December 2020

The influence of a polymorphism at position -857 of the tumour necrosis factor gene on clinical response to etanercept therapy in rheumatoid arthritis

1 reference

12 December 2020

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with c

1 reference

12 December 2020

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

1 reference

12 December 2020

Identification of direct genomic targets downstream of the nuclear factor-kappaB transcription factor mediating tumor necrosis factor signaling.

1 reference

12 December 2020

The response to anti-TNF-α treatment: gene regulation at the bedside

1 reference

12 December 2020

Development of a high-throughput automated analyzer using biochip array technology

1 reference

12 December 2020

Proteomic approach to the diagnosis of acute coronary syndrome: preliminary results.

1 reference

12 December 2020

Comments about the editorial by Bénédicte Mugnier and Jean Roudier entitled "Factors predicting responsiveness to anti-TNFalpha therapy in patients with rheumatoid arthritis: using biotherapies rationally"

1 reference

12 December 2020

Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis

1 reference

12 December 2020

Protein biochip systems for the clinical laboratory.

1 reference

12 December 2020

Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry

1 reference

12 December 2020

Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases

1 reference

12 December 2020

Predictors of response to anti-TNF- therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

1 reference

12 December 2020

10.1111/J.1365-2249.2008.03691.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18549443%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference